HHCP
AZN icon

Hilton Head Capital Partners’s AstraZeneca AZN Stock Holding History

Hilton Head Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.5K Buy
+499
New +$93.9K 0.05% 212
2026
Q1 		– Sell
-500
Closed -$91.8K – 991
2025
Q4 		$91.8K Buy
+500
New +$87.7K 0.05% 204

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Hilton Head Capital Partners's AZN Position: Q2 2026 in Review

Hilton Head Capital Partners opened a new position in AstraZeneca (AZN) in Q2 2026: 499 shares worth $94.5K. The stake represents 0.05% of the portfolio and ranks #212 among its holdings. This is a return to the name: Hilton Head Capital Partners previously reported a position in AZN as recently as Q4 2025.

Hilton Head Capital Partners first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Hilton Head Capital Partners held 499 shares of AstraZeneca worth $94.5K as of Q2 2026.
  • AstraZeneca was a new Hilton Head Capital Partners position in Q2 2026.
  • AstraZeneca made up 0.05% of Hilton Head Capital Partners's portfolio in Q2 2026, its #212 holding.
  • Hilton Head Capital Partners first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.